BACKGROUND: Treatment with estrogen in early menopausal women protects against development of hepatic steatosis and nonalcoholic fatty liver disease but estrogen has undesirable side effects, which negate its beneficial effects in premenopausal and postmenopausal women. Targeted therapies require better understanding of the target sites and mechanisms by which estrogen signaling exerts its protective effects in women. Estrogen receptor α (ERα) is thought to be the primary mediator for estrogen signaling to protect against hepatic steatosis. ERα has several mechanisms for signal transduction: (1) inducing gene transcription by direct binding to specific DNA sequences, (2) inducing tethered transcription with other DNA-binding factors, and (3) stimulating nongenomic action through membrane-associated ERα. However, it is still unclear which mechanisms mediate ERα-dependent protection against hepatic steatosis. METHODS: To understand the mechanisms of estrogen signaling for protection against hepatic steatosis in females, we analyzed the global ERα knockout mouse (αERKO), ERα DNA-binding domain mutant mouse (KIKO) and liver-specific ERα knockout mouse (LERKO) fed high-fat diets (HFD). The KIKO mouse disrupts the direct DNA-binding transcription activity but retains tethered transcription regulation and nongenomic action. Hepatic steatosis was evaluated by scoring the macrovesicular and microvesicular steatosis as well as serum alanine aminotransferase (ALT) levels. We analyzed serum testosterone to assess its correlation with hepatic steatosis. RESULTS: Liver fat accumulation was far greater in HFD-fed αERKO and KIKO females than in HFD-fed wild-type (WT) controls. Conversely, HFD-fed LERKO females did not accumulate excess liver fat. HFD-fed αERKO and KIKO females showed higher microvesicular steatosis and ALT levels than WT controls that correlated with increased serum testosterone levels. CONCLUSIONS: ERα-mediated direct transcription in non-hepatic tissues is essential for estrogen-mediated protection against hepatic steatosis in HFD-fed females. The balance between non-hepatic estrogen signaling and hepatic or non-hepatic testosterone action may control hepatic steatosis.
INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD), defined as the accumulation of excess liver triglyceride (TG; 45% of liver weight), is the most common cause of nonalcohol-related liver disease in adults as well as children. 1 NAFLD is often asymptomatic at presentation but may progress with time to steatohepatitis and cirrhosis requiring liver transplant. NAFLD is associated with the metabolic syndrome (central adiposity, hypertension, insulin resistance and dyslipidemia), which predisposes to type 2 diabetes mellitus and coronary artery disease. Metabolic syndrome is known to be related to lifestyle factors as well as genetic, hormonal and environmental inputs. 2, 3 Several lines of evidence suggest that estrogen signaling modulates the risk of NAFLD. Women with Turner's syndrome, who lack endogenous estrogen production, are at higher risk for development of NAFLD. 4 Likewise, treatment with tamoxifen, an estrogen receptor (ER) antagonist, is associated with the development of NAFLD. 5 Women have lower risk than men until menopause, at which point rates of metabolic syndrome and fatty liver disease rise to meet those of age-matched males. 6 Treatment with estrogen in early menopause protects against development of metabolic syndrome and NAFLD, 7 but it has undesirable side effects, which may negate its benefits in some postmenopausal women. 8 Targeted therapies will require better understanding of the mechanisms by which estrogen signaling exerts its protective effects. Several animal models have been developed to explore mechanisms by which estrogen protects against development of NAFLD. Ovariectomized (OVX) mice lacking estrogen production develop increased liver fat content; these effects are reversible by administration of estradiol (E2). 9 Similar results have been seen in Cyp19 (aromatase) knockout (KO) mice unable to synthesize E2 from androgen precursors. Namely, treatment with exogenous E2 protects Cyp19KO male mice against the development of metabolic syndrome and NAFLD. 10, 11 Interestingly, Cyp19KO females were obese but did not develop hepatic steatosis, 10 suggesting sexual dimorphism of hepatic steatosis regulation. In humans, mutations in the aromatase gene are associated with central adiposity, elevated lipids and insulin resistance; furthermore, treatment with E2 resolved these defects in an aromatase mutant male. 12 Similar features were seen in an adult male with a mutation in the ERα gene. 13 Animals lacking functional ER alpha (ERα) have been shown to have a similar metabolic phenotype to OVX animals, with increased body weight, visceral adiposity and insulin resistance. 14, 15 In contrast, ER beta (ERβ) KO mice show no discernable metabolic or hepatic phenotype. 15 Together, this body 1 of evidence suggests that estrogen action through ERα is the primary protection mechanism of reproductive-aged females against metabolic syndrome and NAFLD. ERα-dependent transcription is mediated through direct binding to specific DNA sequences termed the estrogen-responsive element (ERE). 16 In addition, ERα may activate ligand-dependent transcription through indirect DNA binding with other DNA-binding factors such as AP-1, which is referred to as tethered transcription regulation. 17 Furthermore, a small amount of ERα protein associates with the cellular membrane and transmits E2-mediated signal transduction independent of transcription, called nongenomic action. 18 It is still unclear which mechanisms mediate estrogendependent protection against development of central adiposity, weight gain, insulin resistance and NAFLD. An understanding of the pathways by which estrogenic signaling exerts its protective effects is crucial for the future development of targeted therapies. To that end, we analyzed the ERα DNA-binding domain (DBD) mutant mouse model (KIKO), in which a mutation disrupts the ERE direct binding activity but retains ERE-independent functions, including tethered transcription regulation and nongenomic action. 19 It is also important to understand the tissue-specific functionality of ERα for the development of targeted therapies. We have observed striking differences in the degree of liver fat infiltration seen in ERα KO females compared with wild-type (WT) females. Currently, it is unclear whether these changes in liver fat accumulation are mediated through hepatic ERα signaling or through ERα actions in non-hepatic tissues. Although several groups have described metabolic dysfunction in ERα KO mice, the role of ERα in the liver remains controversial. 20, 21 To further our understanding of hepatic ERα action, we generated and analyzed a liver-specific ERα ΚΟ mouse (LERKO).
In this report, we propose that protection against liver fat infiltration in high-fat diet (HFD)-fed females is regulated by ERα-mediated direct transcription in non-hepatic tissues. Furthermore, we postulate that hepatic steatosis is controlled by the balance between non-hepatic estrogen signaling and hepatic or nonhepatic androgen actions.
MATERIALS AND METHODS Animals
All experiments involving animals were carried out according to US Public Health Service guidelines. Studies were approved by the National Institute of Environmental Health Sciences Institutional Animal Care and Use Committee. The generation of mice lacking exon 3 of Esr1 (Ex3αERKO) has been reported. 22 The generation of KIKO mice has been described previously. 19 To generate the liver-specific Esr1 KO mouse (LERKO), Esr1 f/f mice were crossed with Tg(Alb-cre) mice. The F1 offspring were genotyped and Esr1 f/f -Tg(Alb-cre) mice were used. Animals were maintained on a regular diet (RD; NIH-31, Harlan Laboratory, Indianapolis, IN, USA). On the HFD feeding protocol, animals were maintained with a diet containing 60% kcal% fat (no. 12492, Research Diets, New Brunswick, NJ, USA) beginning at age 9-11 weeks for 10 weeks. Animals were allowed ad libitum access to food during that period. The body weight was determined every week. Glucose tolerance tests and insulin tolerance tests were assessed near the end of the HFD feeding period.
For the 5α-dihydrotestosterone (DHT) treatment experiment, 6-week-old C57BL/6 females were OVX 2 weeks prior to feeding HFD. OVX mice and intact (non-OVX) females were maintained on the HFD for 4 weeks. One week after beginning the HFD feeding, the mice were treated with DHT (0.5 mg per 21 days' release, Innovative Research of America, Sarasota, FL, USA) or placebo pellet for 3 weeks. Animals were randomly assigned to each experimental group. The number of animals required for experimental studies was estimated based on achieving at least 80% power to detect a one point difference in histomorphology. HFD feeding experiment was performed in singlicate in eight mice for each genotype.
Sample collection
The animals were fasted for 4 h before killing with CO 2 . Liver was weighed and a piece of the left lateral lobe was fixed in 10% neutral buffered formalin for histological assessment. For RNA extraction and liver TG measurement, the remaining left lateral lobe was frozen in liquid N 2 and stored at − 70°C. Blood was collected from the descending aorta for measuring serum lipid, hormone and alanine aminotransferase (ALT) levels.
Assessment of liver fat content
Formalin-fixed, paraffin-embedded liver sections were stained with hematoxylin and eosin. Samples were rated with the assistance of a pathologist blinded to genotype for degree of macrovesicular steatosis, in which the cytoplasm is filled by a large fat droplet that displaces the nucleus to the edge of the cell, and microvesicular steatosis, in which small fat vacuoles fill in the cytoplasm without displacing the nucleus. 23 The rating is scaled from 0, no appreciable lipid vesicles to 4, severe steatosis. Liver TGs for DHT experiment were measured as follows: crushed frozen liver (100-120 mg) was homogenized in 1 ml of 5% NP-40 solution. The homogenates were incubated for 5 min at 80-100°C and then cooled to room temperature. The soluble fraction after centrifugation was used for the assay. TGs were measured by the Triglyceride Quantification Assay Kit (Abcam, Cambridge, UK). The values were normalized to sample weight.
Glucose tolerance tests and insulin tolerance tests 
Serum assays
UniCel DxC600 Synchron Clinical Systems (Beckman Coulter, Brea, CA, USA) was used for measurement of ALT, cholesterol and TG levels. The level of nonesterified fatty acids was measured by the colorimetric determination reagent (Wako, Chemical USA, Richmond, VA, USA). The level of adiponectin, insulin and leptin were measured by SECTOR Imager 2400 (MSD, Rockville, MD, USA) using the Meso Scale Discovery Kits (Mouse Adiponectin Kit, Mouse Metabolic Kit for insulin and leptin, MSD). Total free testosterone levels were analyzed by enzyme immunoassay assay using a kit (CLIA Kit for Testosterone; UCSN, China).
Tissue protein extractions and western blotting analyses
Total protein homogenates from liver were prepared and 20 μg of protein was used for western blotting analysis. Proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and subsequently transferred to nitrocellulose membranes. Blots were incubated overnight at 4°C with primary antibody for ERα (1:650; MC-20; Santa Cruz Biotechnology, Dallas, TX, USA) or β-tubulin (1:1000; H235; Santa Cruz Biotechnology). The blots were washed then incubated with horseradish peroxidase-conjugated anti-rabbit IgG (1:5000). Signal was developed using ECL Plus reagent (GE Healthcare, Chalfont-St-Giles, UK).
Microarray
Total RNA was extracted from liver tissue using TRIzol (Invitrogen, Carlsbad, CA, USA). Microarray analysis was performed by NIEHS molecular genomics core laboratory using the Affymetrix Mouse Genome 430 2.0 GeneChip arrays (Affymetrix, Santa Clara, CA, USA). Arrays were scanned in an Affymetrix Scanner 3000 and data were obtained using the GeneChip Expression Console Software (Ver. 1.2, Affymetrix) using the MAS5 algorithm to generate CHP files. The resulting data were processed using the OmicSoft Array Studio (Ver. 6.0) software (Qiagen, Manchester, Germany). In order to identify differentially expressed probes, analysis of variance was used to determine if there was a statistical difference between the means of groups. The analysis was performed with setting parameters of at least two-fold difference and significance at Po0.01. Pathway analysis was performed using the Ingenuity software (Qiagen).
Statistical analysis
All data are represented as mean ± s.e.m. Statistical analyses were performed by GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA, USA). Analytical methods used for each experiment are specified in figure legends. Significance level was set at Po0.05 for every analysis.
Estrogen receptor α for liver steatosis prevention S Hart-Unger et al RESULTS ERα null females develop hepatic steatosis after HFD feeding while WT female mice are resistant HFD-fed ERα null (Esr1
; αERKO) females had significantly higher body weights than WT (Esr1 +/+ ; WT) females ( Figure 1a , circle symbols). In contrast, the body weights of males did not differ between genotypes (Figure 1a , triangle symbols). After 4 weeks of HFD feeding, the body weights of αERKO females were comparable to those of males. Although WT females did not develop liver steatosis after prolonged HFD feeding, αERKO females showed . Two-tailed t-test (unpaired) was performed for comparing the difference between WT and KO (e and f). *P o0.05, **Po 0.01, ***Po 0.001, ****P o0.0001. All data are represented as mean ± s.e.m.
significant liver fat infiltration, comparable in magnitude to WT and αERKO males (Figure 1b) . Blinded histological ratings of macrovesicular steatosis ( Figure 1c ) and microvesicular steatosis ( Figure 1d ) were performed to evaluate the severity of liver steatosis. αERKO females have higher steatosis ratings than WT female controls, while no difference is seen between genotypes in males. Total liver weights of αERKO females were significantly higher than those of WT controls (Figure 1e ) and the proportion of liver weight to body weight (relative liver weight) was also higher (Figure 1f ). Serum ALT level, a marker of hepatic dysfunction, trended higher in αERKO females than in WT controls. ALT level in WT males was higher than in WT females (Figure 1g ). ALT was elevated in αERKO females fed a HFD but not a RD (Figure 1h ).
ERα DBD mutant females develop hepatic steatosis after HFD feeding To determine whether protection against hepatic steatosis in WT females requires ERα-mediated transcription through direct ERE binding, we analyzed ERα DBD mutant (Esr1 AA/ − ; KIKO) females and heterozygous littermate females (Esr1 +/ − ; control). No statistical differences in body weight were noted between KIKO females and controls until 4 weeks after beginning HFD feeding (Figure 2a) . The rate of increase in body weight of KIKO females was not as dramatic as the rate of increase in αERKO females, which was noted within 2 weeks of the dietary change (Figure 1a) . The accumulation of liver fat in KIKO females was significant compared with controls (Figure 2b) . In blinded histological ratings, KIKO females had significantly higher ratings of macrovesicular steatosis (Figure 2c ) and microvesicular steatosis (Figure 2d ) compared with controls. Total liver weights (Figure 2e ) and relative liver weights ( Figure 2f ) were significantly higher in KIKO females than in controls. Serum ALT levels in KIKO females, such as αERKO females, were increased compared with controls ( Figure 2g ). These results suggest that transcriptional activity through direct ERE binding of ERα mediates the estrogen-dependent protection against hepatic steatosis.
The levels of serum lipids were not changed in ERα mutant females Consistent with the hepatic steatosis phenotype, liver TG content was significantly higher in HFD-fed αERKO and KIKO females Figure S1e) . αERKO females demonstrate impaired glucose tolerance As clinically hepatic steatosis is often accompanied by hepatic insulin resistance, 24 we performed glucose tolerance tests and insulin tolerance testing in HFD-fed αERKO and KIKO females to evaluate the effect of ERα signaling on whole body glucose metabolism. Fasting serum glucose levels of αERKO and KIKO females were significantly higher than control females (Figure 3e) . When subjected to an IP glucose challenge, αERKO females had higher glucose values than WT control by 120 min postinjection (Figure 3a) . KIKO females showed higher glucose levels than control females at 20 min but similar levels by 60 min (Figure 3b) . Following an IP injection of insulin, the magnitude of glucose level decline in αERKO females was significantly less than in control females, suggesting insulin resistance (Figure 3c ). The trend was similar but less striking in KIKO females than in αERKO females (Figure 3d ). Fasting insulin level, which generally reflects hepatic insulin sensitivity, was significantly higher in αERKO females but not in KIKO females (Figure 3f ). These results suggest that EREindependent ERα action is involved in insulin-mediated glucose homeostasis.
Evaluation of hepatic ERα involvement in protection against hepatic steatosis using microarray As the observations of KIKO females suggested that the EREdependent transcription regulation of ERα is essential for protection against hepatic steatosis during HFD feeding, we performed gene profiling by microarray to analyze ERα-regulated hepatic genes in HFD-fed females. We focused on the gene set that was differentially expressed in RD-and HFD-fed WT liver but not differentially expressed in RD-and HFD-fed αERKO liver (Supplementary Material; Supplementary Figure S2a) . Theoretically, this gene set includes ERα-associated HFD-regulated genes in the liver. We performed ingenuity pathway analysis (IPA) for this gene cluster (849 genes) to discover the potential upstream regulators. IPA predicted that β-catenin (CTNNB1) was the toprated upstream regulator (P-value; 3.94E-07). Interestingly, DHT, the active endogenous ligand for the androgen receptor, appeared as the second-rated regulator (P-value; 2.24E-06). Surprisingly, IPA prediction for a role of ERα (ESR1) and estrogen were rated very low (P-values; 1.04E-03 and 4.82E-04, respectively) (Supplementary Figure S2b) .
Liver-specific ERα KO females do not develop hepatic steatosis after HFD feeding To determine whether hepatic ERα transactivation is essential for estrogen-dependent protection against steatosis, we generated liver-specific ERα KO mice (Esr1 f/f -Tg(Alb-cre); LERKO). ERα protein was detected in the uterus of control (Esr1 f/f ) and LERKO females but no appreciable signal was visible in LERKO liver tissue (Figure 4a) . During the HFD feeding, LERKO females gained weight at rates comparable to controls (Figure 4b ). After HFD feeding, very little steatosis was present in either LERKO or control females (Figure 4c ). In blinded histological ratings, there were no differences between the two genotypes in macrovesicular steatosis (Figure 4d ) and microvesicular steatosis (Figure 4e ). This is in marked contrast to the steatosis results detected in αERKO ( Figure 1 ) and KIKO (Figure 2 ) females. The total liver weight and relative liver weight of LERKO females were similar to controls (Figure 4f and g ). Moreover, ALT levels did not differ between the two genotypes (Figure 4h ). In addition, the levels of TGs, total cholesterol and non-esterified fatty acids did not differ between genotypes (Figure 4i ). HFD-fed LERKO and control females showed indistinguishable profiles of glucose tolerance (Figure 4j ) and insulin sensitivity assessed by IP insulin tolerance testing (Figure 4k ). In addition, fasting plasma insulin levels did not differ between these genotypes (Figure 4l ). These results suggest that hepatic ERα signaling has a limited role in hepatic fat accumulation or systemic glucose metabolism.
Adipokine levels in ERα mutant females As leptin and adiponectin, the adipocyte-secreted metabolic effectors, have been implicated in NAFLD, 25 we analyzed serum leptin and adiponectin levels in HFD-fed WT and ERα mutant females and RD-fed WT and αERKO females. Although serum leptin levels were elevated in HFD-fed females compared with RD-fed females regardless of genotype, the leptin levels of HFD-fed αERKO and KIKO females were higher than HFD-fed LERKO and WT controls (Figure 5a) . The leptin level correlated positively with adiposity. The serum adiponectin level was suppressed in αERKO and KIKO females compared with WT controls. The lower adiponectin level in αERKO females was observed regardless of diet (Figure 5b ). The adiponectin level correlated inversely with adiposity. It has been reported that testosterone is a possible regulator of adiponectin levels, 26 so we analyzed serum testosterone levels in the mice. The profile of serum testosterone level correlated inversely with serum adiponectin level (Figure 5c ).
The balance between E2 and testosterone correlates with HFDinduced hepatic steatosis Because we found a correlation between serum testosterone and adiposity in the ERα mutants, we analyzed the effect of Figure 5 . (a) Serum leptin levels of WT, αERKO (KO), KIKO and LERKO females (F) after 10 weeks HFD feeding and RD-fed WT and KO females. (b) Serum adiponectin levels of WT, αERKO (KO), KIKO and LERKO females after 10 weeks HFD feeding and RD-fed WT and KO females. (c) Serum testosterone levels of WT, αERKO (KO), KIKO and LERKO females after 10 weeks HFD feeding and RD-fed WT and KO females. One-way analysis of variance with Tukey's multiple comparisons test were performed for comparing the difference between groups. The right panel in each graph shows the value of WT and αERKO (KO) males (M) after 10 weeks HFD feeding. Twotailed t-test (unpaired) was performed for comparing the difference between WT and KO males. **P o0.01, ***Po0.001, ****P o0.0001. All data are represented as mean ± s.e.m.
testosterone on the early phase of hepatic steatosis in females. HFD-fed OVX and intact WT females were implanted with a pellet containing DHT or placebo for 3 weeks. The body weight of HFD-fed OVX mice was significantly increased compared with intact females. Treatment with DHT enhanced the body weight gain of OVX females but not of intact females (Figure 6a) . Notably, macrovesicular steatosis was not observed after 4 weeks of HFD feeding; however, microvesicular steatosis was observed in all DHT-treated OVX females, which was different from placebotreated OVX mice or intact females (Figures 6b and c) . Consistent with the score of microvesicular steatosis, the liver TG content was higher in the HFD-fed OVX mice compared with that in intact females. Furthermore, the hepatic TG level in OVX mice was significantly increased by DHT treatment but not in intact females (Figure 6d) . The serum ALT level was significantly increased in OVX mice compared with that in intact females. The ALT level in DHTtreated OVX mice was slightly higher than in placebo-treated OVX mice but not statistically significant (Figure 6e ).
DISCUSSION
Previous studies by Park et al. 27 reported that KIKO females fed RD and HFD did not become obese compared with αERKO females, suggesting that ERE-independent E2-ERα signaling can prevent obesity. The report suggested that differential locomotor activities mediated by hypothalamic ERα function between αERKO and KIKO may explain the differential regulation of obesity. 27 In contrast, our studies of KIKO mice suggest that ERE-independent E2-ERα signaling does not prevent HFD-mediated obesity and hepatic steatosis, though the initial body weight gain of KIKO mice is slower than that of αERKO mice (Figures 1a and 2a) . It should be noted that the composition of diet differed between our study and that of Park et al. 27 We used a 60% kcal% fat diet (D12492; Research Diets) while the other group used a 45% kcal% fat diet (D12451; Research Diets). These HFDs (D12492 and D12451) contain different amount of fat (34.9% and 24%, respectively) and carbohydrate (26.3% and 41%, respectively). Notably, D12492 diet, which we used, contains 1.5 times more cholesterol than D12451. One-way ANOVA with Tukey's multiple comparisons test were performed for comparing the difference between groups (c-e). *Po 0.05, **Po 0.01, ***P o0.001, ****P o0.0001. NS denotes no significant difference. All data are represented as mean ± s.e.m.
Our results suggest that an excess of dietary lipid may diminish the preventive effect of ERE-independent E2-ERα signaling for obesity In contrast to αERKO mice, previous reports found normal insulin sensitivity in KIKO females. 27, 28 We observed that the insulin response in HFD-fed KIKO female was not statistically different from the control mice and fasted KIKO females had lower insulin than αERKO, even though the fasting blood glucose level in KIKO females was higher than in control mice (Figure 3e) . Overall, our findings and the previous reported results suggested that KIKO females are more sensitive to insulin than αERKO. This result suggests that ERE-independent E2-ERα signaling is involved in the maintenance of insulin-mediated glucose homeostasis and that it may be independent of its protection against obesity.
We previously reported that the mutated DBD of KIKO can bind to progesterone receptor-, glucocorticoid receptor-and androgen receptor-binding DNA sequences and the KIKO mutant ERα binds to progesterone receptor-binding elements in the uterus and compromises progesterone signaling. 29 At the present time, we have no evidence that the KIKO mutant ERα bound to androgen receptor-binding sequences in the liver or other tissues that would compromise androgen signaling. However, it would be interesting to re-evaluate the ERE-independent ERα action in future studies using another ERα DBD mutant mouse model, such as Esr1 EAAE/EAAE mouse (B6;129P2-Esr1 tm2.1Gsc ). 29, 30 Several groups reported the functionality of hepatic ERα using the LERKO mouse. 20, 21 Zhu et al. 20 reported that hepatic ERα signaling is required for HFD-mediated insulin resistance and prevention of liver fat accumulation following OVX. On the other hand, Matic et al. 21 used intact mice to conclude that hepatic ERα action is not the responsible factor for the insulin resistance observed in αERKO females. Consistent with the observations of Matic et al., 21 the phenotypes of our LERKO mouse were indistinguishable from control females (Figure 4) . The discrepancy between our results and that of Zhu et al., 20 who used OVX mice, would suggest that hepatic ERα may have some functionality but that non-hepatic ERα mediated signaling has the primary role in preventing hepatic steatosis under the control of gonadal hormones.
We demonstrated that HFD-fed αERKO females showed severe hepatic steatosis compared with WT females. In contrast, severe liver steatosis was observed in both genotypes of HFD-fed males compared with females ( Figure 1b) . It has been postulated that an insufficiency of estrogen rather than an excess of testosterone is likely to induce hepatic steatosis because E2 treatment normalized body fat content in Cyp19KO male mice. 10 Additionally, fat accumulation in OVX rodents is reversible with reintroduction of E2. 9 We have shown that αERKO females have high serum testosterone similar to males. However, it was unclear whether the higher testosterone level in αERKO females affects hepatic steatosis. As we demonstrated here, DHT treatment enhanced liver fat accumulation in OVX mice but not in intact females ( Figure 6 ). These observations suggest that testosterone can stimulate hepatic steatosis in females but E2-mediated protective effect overcomes that event. Interestingly, IPA analysis suggested that DHT is a high-rated upstream regulator in differentially regulated genes in HFD-and RD-fed WT female liver, while ESR1 and estrogen were lower-rated factors. Furthermore, DHT induced liver fat infiltration but not serum ALT in the early phase of hepatic steatosis. Together with our findings in LERKO mice, these results suggest that testosterone-mediated hepatic signaling enhanced HFD-derived fat accumulation in the liver, leading to hepatocellular inflammation, whereas E2 protected hepatic steatosis through the non-hepatic tissue derived factor(s).
Beta-catenin was ranked as the highest upstream factor in our IPA analysis. Recently, Behari et al. 31 reported that liver-specific β-catenin-overexpressing transgenic (Tg(Alb-β-cateninS45D)) male mice showed hepatic steatosis and increased hepatic TG levels when fed HFD but not RD. In contrast, the liver-specific β-catenin KO male mice showed lower hepatic TG levels even in the HFD-fed state. These results support our IPA analysis result. It would informative to evaluate how E2-ERα signaling might regulate Wnt/ β-catenin signal in the HFD-fed mouse liver for protecting hepatic steatosis in future studies.
We demonstrated the importance of ERE-dependent ERα transcription regulation in protecting against hepatic fat accumulation in HFD-fed female mice. However, hepatic ERα signaling does not have a critical role in this protection mechanism. Rather, our results suggest that hepatic steatosis is controlled by a balance between non-hepatic estrogen signaling and hepatic or non-hepatic androgen actions. The balance between E2 and testosterone levels in perimenopausal and menopausal women may be an important parameter to control the risk of metabolic syndrome and NAFLD.
